Because these medications target different physiological systems, combining them addresses multiple metabolic defects simultaneously rather than competing for the same pathway
The non-randomized trial by Pettegrew et al 12 assessed with ROBINS-I, showed a critical risk of bias from confounding and serious risk from participant selection, although other domains were low risk
The short half-life means drug accumulation from a double dose can cause severe GI side effects
Given that obesity is a chronic and relapsing disease, it is important to understand the effectiveness of different strategies to maintain WL: TRIUMPH-6 (NCT06859268) will assess changes in bodyweight at 116 weeks in individuals with obesity who have completed 80 weeks of retatrutide, comparing continued treatment at high or low doses of retatrutide versus switching to placebo for the last 36 weeks
Obesity meets its match
78 HP 160 CAGRILINTIDE Long-Acting Amylin Analog ALIASES Cagrilintide, AM833, long-acting amylin analog CLASS Synthetic amylin analog once-weekly dual amylin/calcitonin agonist FORMULA CHNO (approx) SEQUENCE 37-residue amylin analog with C20-fatty-acid albumin tether HALF-LIFE ~7 days (once-weekly dosing) ROUTES Subcutaneous (Phase 2/3 clinical) MECHANISM OF ACTION Long-acting amylin analog